Skip to main content

Table 3 Continuous Subcutaneous Infusions for the MET group

From: Continuous subcutaneous infusion for pain control in dying patients: experiences from a tertiary palliative care center

Age-group

Patient

Malignancy

Max Methadone dose/24 h. in CSCI (mg)

Local toxicity

Regular opioid in CSCI

Other drugs in CSCI

40–49

1

Liver

20

no

morphine

midazolam, haloperidol

 

4

Thyroid

10

no

hydromorphone

midazolam, hyoscine butylbromide, metoclopramide

60–69

2

Abdominal

5

no

oxycodone

hyoscine butylbromide

 

6

Lung

5

no

oxycodone

midazolam, hyoscine butylbromide, haloperidol

 

7

Lung

10

no

hydromorphone

midazolam, metoclopramide

 

13

Lung

5

no

hydromorphone

midazolam, hyoscine butylbromide, haloperidol

70–79

5

B-cell lymfoma

7.5

yes

oxycodone

midazolam

 

8

Bladder

5

no

oxycodone

 
 

9

Bladder

20

no

hydromorphone

midazolam, haloperidol

 

10

Lung

10

no

hydromorphone

midazolam, haloperidol

 

11

Lung

5

no

hydromorphone

midazolam, haloperidol

80–89

3

Colon

5

no

oxycodone

 
 

12

Merkel cell

10

no

oxycodone

midazolam, haloperidol

  1. This table describes the characteristics of the 13 patients who were prescribed methadone in continuous subcutaneous infusion (CSCI), the MET group. By local toxicity is meant whether or not skin erythema occurred.